0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India
Donald Trump announced a phased tariff plan on imported generic medicines that will begin in August 2026, increasing to 200 percent over three years. This policy aims to reshore pharmaceutical production to the U.S., significantly impacting India, a key supplier of affordable generics. The tariffs introduce uncertainty into ongoing bilateral trade negotiations between the two countries.